Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

NCT04610658 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped DLTs

Conditions

Small-cell Lung Cancer
Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Lurbinectedin

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]